A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Cryptenamine
Imidapril
Desipramine may decrease the antihypertensive activities of Imidapril.
Cryptenamine
Angiotensin 1-7
Desipramine may decrease the antihypertensive activities of Angiotensin 1-7.
Cryptenamine
Rauwolfia serpentina root
Desipramine may decrease the antihypertensive activities of Rauwolfia serpentina root.
Cryptenamine
Trimazosin
Desipramine may decrease the antihypertensive activities of Trimazosin.
Cryptenamine
Temocapril
Desipramine may decrease the antihypertensive activities of Temocapril.
Cryptenamine
Ferulic acid
Desipramine may decrease the antihypertensive activities of Ferulic acid.
Cryptenamine
Diethylnorspermine
Desipramine may decrease the antihypertensive activities of Diethylnorspermine.
Cryptenamine
Dexpropranolol
Desipramine may decrease the antihypertensive activities of Dexpropranolol.
Cryptenamine
Spirapril
Desipramine may decrease the antihypertensive activities of Spirapril.
Cryptenamine
Saprisartan
Desipramine may decrease the antihypertensive activities of Saprisartan.
Cryptenamine
Cilazapril
Desipramine may decrease the antihypertensive activities of Cilazapril.
Cryptenamine
Terazosin
Desipramine may decrease the antihypertensive activities of Terazosin.
Cryptenamine
Deserpidine
Desipramine may decrease the antihypertensive activities of Deserpidine.
Cryptenamine
Cryptenamine
Desipramine may decrease the antihypertensive activities of Cryptenamine.
Mefenamic acid
Lithium hydroxide
The risk or severity of serotonin syndrome can be increased when Nefazodone is combined with Lithium hydroxide.
Mefenamic acid
Lithium citrate
The risk or severity of serotonin syndrome can be increased when Lithium citrate is combined with Nefazodone.
Mefenamic acid
Lithium carbonate
The risk or severity of serotonin syndrome can be increased when Nefazodone is combined with Lithium carbonate.
Mefenamic acid
Pralsetinib
The serum concentration of Nefazodone can be increased when it is combined with Pralsetinib.
Mefenamic acid
Satralizumab
The serum concentration of Nefazodone can be decreased when it is combined with Satralizumab.
Mefenamic acid
Oliceridine
The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Nefazodone is combined with Oliceridine.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3